Novavax’s stock slides 16% after FDA puts clinical hold on COVID and flu vaccine candidates

By / / Finance / 1 minute of reading




Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.



Source link

About The Author

Avatar of Amanda Pierce
Amanda Pierce is a writer who has covered sports, education, and tech for Highland Loch Press. She also writes about her hobbies—which include hiking, traveling to new places, and cooking.

Start typing and press enter to search

Scroll to Top